Healthcare - Tuesday, December 15, 2009 15:29 - 0 Comments

EntreMed Inc. ENMD Market Open’s 3.23% in Morning Session

EntreMed, Inc. today announced the receipt of $1.7 million in royalty revenue from sales of Thalomid through the third quarter compared to estimate royalty revenue of $3.3 million. In addition, the Company anticipates a decrease in fourth quarter and projected income for fiscal 2009. The variation in estimated and actual income for the third quarter will be reflected in the fourth quarter financial outcome.

Last Trade: 0.88
Trade Time: 10:09am ET
Change: Down 0.03 (3.23%)
Prev Close: 0.91
Open: 0.88
Day’s Range: 0.87 – 0.90
52wk Range: 0.15 – 1.53
Volume: 29,649
Avg Vol (3m): 607,720
Market Cap: 77.30M

About EntreMed Inc.

EntreMed, Inc. (EntreMed) is a clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells and the blood vessels that nourish them. The Company focused on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes. The Company has four compounds in clinical development with a pipeline of orally-active, multi-mechanism drugs for the treatment of cancer including; MKC-1, a cell cycle inhibitor, Panzem (2-methoxyestradiol or 2ME2), and ENMD-1198, an antimitotic agent. EntreMed also has active investigational new drug (IND) for its Aurora A/angiogenesis kinase inhibitor, ENMD-2076, and Panzem for rheumatoid arthritis.